A Vision for Self-Sufficiency
Grifols Egypt for Plasma Derivatives (GEPD) was established in 2021 with the goal of achieving national self-sufficiency in plasma-derived medicines, a fully self-contained end-to-end capability to source plasma, manufacture plasma therapeutics and get them to patients. Localizing one of the safest and most technologically advanced biopharmaceutical industries, Grifols Egypt is also strengthening Egypt’s healthcare system and enhancing the quality of life for thousands of its citizens. Through a strategic joint venture between the Egyptian government, represented by the National Service Projects Organization (NSPO), and Grifols, a global healthcare leader with over a century of expertise in manufacturing plasma-derived medicines, Grifols Egypt, the first initiative of its kind in the country and broader region is driving the National Project for Plasma Derivatives forward.
A Comprehensive Impact
Grifols Egypt is making a significant impact across many areas:
- Healthcare: In addition to achieving 100% self-sufficiency in essential plasma-derived medicines such as immunoglobulin, albumin and factor VIII for Egyptian patients, the initiative enhances the country’s overall health through periodic health tests and checkups for plasma donors.
- Society: Creating over 2,500 high-skilled jobs focused especially on career opportunities for young talents and women, Grifols Egypt ultimately has a broader positive contribution to Egyptian society.
- Economy: Localizing the plasma industry to reduce reliance on imports, which also ensures patient access to critical medicines.
- Environment: Grifols Egypt is implementing green building practices, including the integration of clean solar energy, as well as effective waste management solutions and water treatment systems to reduce the company’s carbon footprint.
1000+
employees
2500+
planned employment opportunities
20
planned DCs
Achieved 100%
self-sufficiency
The First Fully Integrated Plasma Platform in Africa and the Middle East
Grifols Egypt has opened 11 donation centers of a planned network of 20 plasma donation centers, all adhering to the highest international standards of quality and safety to ensure the well-being of donors and patients.
The company’s donation centers are the first outside North America and Europe to be certified by the Plasma Protein Therapeutics Association’s (PPTA) International Quality Plasma Program, the industry’s recognized authority on quality and safety.
Manufacturing Facility: A Milestone in Plasma Medicine
Egyptian plasma will be manufactured at a pioneering state-of-the-art facility in the New Administrative Capital’s Medical City. Spanning 105,000 square meters, it will have an initial processing capacity of over 1 million liters of plasma annually, with the potential to be expanded in the future. While under construction, Egyptian plasma is made into medicine in the Grifols plant in Parets de Vallès (Barcelona), Spain, before returning to Egypt as final medicinal products ready to be administered to patients.
Plasma Logistics Center: Ensuring Quality and Safety
The Plasma Logistics Center (PLC), currently under construction, will play a critical role in Grifols Egypt’s supply chain. It is responsible for the final quality approval of each plasma unit before it is converted into lifesaving medicines for Egyptian patients. Plasma is transported to the PLC in purpose-built refrigerated trucks, each unit undergoing individual quality control before being released for production.
Testing Laboratory: Safeguarding Plasma Quality
The Grifols Egypt campus will also include a cutting-edge laboratory to test the increasing amounts of plasma donations from the company’s growing plasma donation center network (testing is currently taking place in the 6th of October building).
Lab excellence – testing each plasma donation to ensure it adheres to the highest quality and safety standards – plays a vital role in safeguarding the well- being of our plasma donors and patients.
Empowering Egyptian Talent
The company is committed to investing in human capital through the establishment of the region’s first training academy specializing in the plasma industry. Modeled after Grifols’ international training academy in the U.S., this initiative delivers cutting-edge training programs led by top Egyptian and international experts.
Grifols Egypt: A Commitment to National Healthcare and Security
With a combination of global expertise and national dedication, Grifols Egypt is setting new standards in the plasma industry. By developing a fully integrated plasma platform, the company is ensuring Egypt’s self-reliance in plasma-derived medicines, preserving national security and fulfilling its motto: "Our medicine in our hands."